United Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary Lung Rx, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for inhaled treprostinil for the treatment of pulmonary arterial hypertension. The NDA will be subject to a standard review period of 10 months, with a targeted user fee deadline of April 30, 2009.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.

For any corrections of factual information, or to contact the editors please use our feedback form .

Hypertension or high blood pressure is a risk factor for heart disease, stroke and other cardiovascular conditions. Fortunately, it can be controlled. Tune in to find out how...

Controlling blood sugar levels are crucial for people with diabetes. But equally important is blood pressure control. High blood pressure and diabetes often occur together and if left untreated can lead to serious consequences. Join experts as they discuss the link between these two conditions, who...

This is cache, read story here